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Edited by Felix WielandAbstract Mammalian cells acquire tolerance against multiple
stressors through the high-level expression of stress-responsible
genes. We have previously demonstrated that protein-disulﬁde
isomerase (PDI) together with ubiquilin are up-regulated in
response to hypoxia/brain ischemia, and play critical roles in
resistance to these damages. We show here that ubiquilin
interacts preferentially with poly-ubiquitin chains and 19S
proteasome subunits. Taken together, these results suggest that
ubiquitin could serve as an adaptor protein that both interacts
with PDI and mediates the delivery of poly-ubiquitylated
proteins to the proteasome in the cytosol in the vicinity of the
endoplasmic reticulum membrane.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The ubiquitin (Ub)-proteasome system is the major non-ly-
sosomal proteolytic pathway in eukaryotes. Proteins are tar-
geted for destruction by the addition of poly-Ub chains to a
lysine residue of the substrate proteins. The ubiquitylation
process involves E1 (Ub-activating enzyme), E2 (Ub-conju-
gating enzyme), and E3 (Ub-ligase) [1–3]. These multi-Ub-
tagged substrates are recognized and degraded by the 26S
proteasome.
Ubiquilin is a Ub-like (UBL) protein and has an N-terminal
UBL domain and a C-terminal Ub-associated (UBA) domain
in its structure. UBL proteins are classiﬁed into two subclasses,
designated as type 1 and type 2 [1]. Type 1UBL proteins such as
SUMO and NEDD8 are covalently linked to target proteins in
a manner analogous to that of Ub and are implicated in post-
transcriptional protein modiﬁcation [1,4]. On the other hand,
type 2 UBL proteins possess UBL domains at their N-terminus,
but do not form conjugates with substrate proteins [1]. How-* Corresponding author. Fax: +81-11-706-4987.
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doi:10.1016/j.febslet.2004.04.031ever, extensive characterization of type 2 UBL proteins has
elucidated that they play critical roles in Ub-dependent prote-
olysis. The physiological function and interactions among poly-
ubiquitylated substrates, the proteasome, and UBL proteins
have not been completely elucidated in mammalian cells.
We have previously succeeded in identifying that protein-
disulﬁde isomerase (PDI) is up-regulated in response to hypoxia/
brain ischemia and plays an important function in resistance to
these damages [5]. Furthermore, PDI associates preferentially
with ubiquilin, a mammalian type 2 UBL protein [6]. Interest-
ingly, PDI together with ubiquilin has a protective role against
hypoxic stress. In the present study, we indicate that ubiquilin
may be associated with not only poly-Ub chains through the
UBA domain but also with two subunits of 19S proteasome
through the UBL domain. These results suggest that ubiquilin
may serve as a shuttle factor that regulates the translocation of
proteolytic substrates to the proteasome in concert with PDI
under a brain ischemic or hypoxic condition.2. Materials and methods
2.1. Materials
Anti-FLAG M5 monoclonal antibody (mAb) and anti-HA poly-
clonal antibody (pAb) were purchased from Sigma (St. Louis, MO)
and Santa Cruz Biotech (Santa Cruz, CA), respectively. The yeast two-
hybrid system and anti-b-actin mAb were purchased from CLON-
TECH (Palo Alto, CA). Anti-poly-Ub mAb was purchased from
Nippon Bio Test Lab (Tokyo, Japan). Anti-calnexin NT and CT pAbs
were purchased from StressGen (Victoria, Canada). All other reagents
were obtained from Sigma.
2.2. Plasmids
Recombinant GST-ubiquilin and truncated mutants were generated
as previously described [6]. Full-length Ub amino acid 52-residue
ribosomal protein fusion (UBA52) and Ub cDNA were isolated from
human neuroblastoma RNA by RT-PCR. The cDNAs encoding ori-
ginal human Rpn were kindly provided by Dr. Kawahara and Dr.
Tanaka. Human Rpn constructs tagged with an HA epitope at the N-
terminal (HA-Rpn1, HA-Rpn2, and HA-Rpn3) and at the C-terminal
(Rpn10a-HA and Rpn10e-HA) were subcloned into mammalian ex-
pression vector pCR3.1, respectively.
2.3. Yeast two-hybrid assay
Plasmid pAS2-1 harboring cDNA for the UBA domain (Q541-S587)
of the ubiquilin was generated as bait for library screening. Yeast two-
hybrid screening was performed with a pretransformed cDNA library
derived from human adult brain mRNA (CLONTECH) according to
the manufacturer’s protocol [7].
2.4. In vitro binding assay
GST-fusion proteins were prepared from Escherichia coli BL21
(DE3) as described previously and used for pull-down assay [6].blished by Elsevier B.V. All rights reserved.
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lin-proteasome, SH-SY5Y and HEK 293 cells were lysed in lysis buﬀer
containing 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM DTT, 5
mM EDTA, 1% Triton X-100, 0.1 lM MG132, 5 mM N-ethylmalei-
mide, and 10% glycerol, with complete protease inhibitors (Roche
Diagnostics). For GST-pull down, lysates were incubated with either
GST-ubiquilin or GST-truncated mutants immobilized on a glutathi-
one–Sepharose 4B column (Amersham Pharmacia Biotech, Bucking-
hamshire, UK) at 4 C for 4 h, followed by ﬁve washes with 1 ml of
lysis buﬀer. Ubiquilin-associated UBA52, Ub, and proteasome were
detected by SDS–PAGE/Western blot assay using anti-FLAG mAb,
anti-poly-Ub mAb, and anti-HA pAb with an enhanced chemilumi-
nescence detection method.
2.5. Immunoprecipitation and Western blotting analysis
Cell extracts were prepared in lysis buﬀer containing 50 mM Tris–
HCl (pH 7.5), 150 mMNaCl, 1 mMDTT, 5 mM EDTA, 1% Triton X-
100, 0.1 lMMG132, 5 mM N -ethylmaleimide, and 10% glycerol, with
complete protease inhibitors. For the co-immunoprecipitation assay,
immunoprecipitates were prepared using anti-FLAG tag antibody M2
conjugated to agarose. Immune complexes were resolved by SDS–
PAGE and then analyzed by Western blotting assay using anti-HA
pAb and anti-poly-Ub mAb [8–11].3. Results
3.1. Ubiquilin associates with poly-Ub
To explore the detailed functions of ubiquilin, we employed
a yeast two-hybrid system to screen a human fetal brain cDNA
library constructed in a pACT2 plasmid encoding the GAL4Fig. 1. Association of ubiquilin with UBA52 and Ub. (A) Construction of t
teraction of ubiquilin with UBA52 and Ub by yeast two-hybrid system. In
prototrophic growth (top panel) and b-galactosidase activity (bottom panel). T
and bottom panel). (C) Recombinant GST and GST-ubiquilin were incubate
bound materials were eluted, fractionated by Tris–tricine 15% SDS–PAGE, a
of mono-Ub are indicated at the left of the gel. (D) Co-immunoprecipitation
with plasmid for FLAG-ubiquilin in the presence or absence of HA-Ub cDN
FLAG mAb. The immune complex bound to protein G–Sepharose beads wa
by Western blotting using anti-HA pAb (ﬁrst panel) and anti-FLAG mAb (t
anti-HA pAb (second panel), The positions of mono-Ub are indicated at theactivation domain using the C-terminal UBA domain in
ubiquilin as bait (Fig. 1A, top panel). From among 1 107
transformants, several independent clones were isolated as
determined by activation of the his, ade, and lacZ reporter
genes. A BLAST search revealed that one of the isolated clones
was UBA52, a clone consisting of Ub cDNA fused with
ribosomal protein [12–14]. We next attempted to determine the
site of the interaction between ubiquilin and UBA52 using a
yeast two-hybrid system. As shown in Fig. 1B, the C-terminal
of ubiquilin is suﬃcient for interaction with full-length
UBA52. Since UBA52 is a Ub fusion protein, we investigated
whether Ub also interacts with the C-terminal of ubiquilin.
Interestingly, both Ub and UBA52 could bind to ubiquilin
(Fig. 1B). Then, to conﬁrm whether ubiquilin interacts with
Ub, we employed an in vitro pull-down assay and co-immu-
noprecipitation using lysates in mammalian cells transfected
with ubiquilin and Ub. Cell lysates transfected with HA-tagged
Ub were incubated with GST or GST fused with ubiquilin
(GST-ubiquilin). HA-tagged Ubs were detected in a high
molecular weight smear eluted from the beads binding to GST-
ubiquilin but not from those binding to GST alone (Fig. 1C).
To determine whether the interaction between ubiquilin and
Ub occurs in mammalian cells, human neuroblastoma SH-
SY5Y cells were transiently transfected with FLAG-tagged
ubiquilin together with HA-tagged Ub (Fig. 1D). Whole cell
lysates were immunoprecipitated with anti-FLAG mAb and
then analyzed by Western blotting using anti-HA pAb. Thehe UBA domain of ubiquilin as bait (top panel). (B) The assay for in-
teraction of ubiquilin with UBA52 and Ub was tested by histidine-
he UBA domain of ubiquilin (residues 541–587) was used as bait (top
d with SH-SY5Y extracts transfected with HA-Ub for 4h, and GST-
nd immunoblotted with anti-HA pAb or anti-GST mAb. The positions
between ubiquilin and Ub was performed in SH-SY5Y cells transfected
A. Equal amounts of cell lysates were immunoprecipitated with anti-
s then washed with lysis buﬀer, resolved by SDS–PAGE, and analyzed
hird panel). Total cell lysates were analyzed by Western blotting using
left of the gel.
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precipitates with anti-FLAG antibody from cells co-trans-
fected with HA-Ub (Fig. 1D).
3.2. The interaction domain of ubiquilin with poly-Ub
To determine the domain of ubiquilin required for poly-Ub
binding, several truncated mutants of ubiquilin fused to GST
were expressed in E. coli. GST-fused full-length and truncated
mutants of ubiquilin were applied to glutathione–Sepharose
and then incubated with SH-SY5Y cell extracts. The interac-
tion abilities were examined by immunoblotting analysis with
anti-poly-Ub antibody. As shown in Fig. 2A, the mutants
lacking a UBA domain (residues 113–587) failed to interact
with poly-Ub, whereas wild-type (residues 1–587) and the
mutants containing a UBA domain (residues 113–587 and
541–587) were capable of binding to poly-Ub with high mo-
lecular weight smear. Thus, only the UBA domain of ubiquilin
has a strong ability to bind with poly-Ub. Because type 2 UBL
proteins have been implicated in the accumulation of poly-Ub
chains in cells [15,16], we investigated whether overexpression
of ubiquilin also induces such accumulation. Ubiquilin and the
mutant lacking a UBA domain (residues 1–540) were trans-
fected into human neuroblastoma SH-SY5Y cells, and then the
lysates were subjected to Western blotting with the anti-poly-
Ub mAb. Overexpression of ubiquilin led to the accumulation
of a large number of poly-Ub chains in human neuroblastoma
SH-SY5Y cells, whereas expression of the mutant lacking the
C terminus (residues 1–540) did not (Fig. 2C). This result
suggests that the C-terminal UBA domain of ubiquilin is re-
quired for binding and the increased accumulation of poly-Ub
chains in mammalian cells.Fig. 2. The UBA domain of ubiquilin is required for its binding. (A)
recombinant GST-ubiquilin and GST-truncated mutants were incu-
bated with SH-SY5Y cell extracts for 4 h, and GST-bound materials
were analyzed by Western blotting with the anti-poly-Ub mAb (upper
panel) and anti-GST mAb (lower panel) antibodies. (B) A diagram of
ubiquilin constructs. Binding abilities of the mutants are shown on the
right. (C) HA-tagged ubiquilin (residues 1–587) and HA-tagged dele-
tion UBA of ubiquilin (residues 1–540) were transfected into SH-SY5Y
cells, and proteins from the extracts were resolved by SDS–PAGE and
analyzed by Western blotting using anti-poly-Ub mAb (ﬁrst panel),
anti-HA pAb (second panel), and anti-b-actin mAb (third panel) anti-
bodies.3.3. Ubiquilin interacts with human non-ATPase proteasome
19S subunits
Although hPLIC proteins, which are ubiquilin homologs,
have been reported to interact with some 20S complex subunits
of 26S proteasome [17], little is known about the interaction
with 19S components of 26S proteasome. To examine the
possibility that the 19S complex subunit(s) is capable of in-
teracting with ubiquilin, a GST-ubiquilin fusion protein was
coupled to glutathione–Sepharose beads and incubated with
mammalian cell extracts containing transiently expressed HA-
tagged Rpn1, Rpn2, Rpn3, Rpn10a, and Rpn10e. The abilities
of the subunits to interact with ubiquilin were determined by
Western blotting analysis using anti-HA pAb. As shown in
Fig. 3A, the GST-pull down assay revealed that each of the
subunits Rpn3, Rpn10a, and Rpn10e formed a complex with
ubiquilin. However, the truncated mutant ubiquilin lacking a
UBL domain did not interact with the Rpn3 and Rpn10a
subunits (Fig. 3B). Next, to determine whether ubiquilin binds
to the subunit of 19S proteasome in vivo, immunoprecipitation
was performed using lysates in HEK 293 cells overexpressing
Rpn10a-HA with or without FLAG-ubiquilin. Whole lysates
were immunoprecipitated with anti-FLAG mAb and thenFig. 3. Ubiquilin binds to Rpn3, Rpn10a, and Rpn10e through its
UBL domain. (A) Human 293 cell lysates were transiently transfected
with several vectors, HA-tagged Rpn1, Rpn2, Rpn3, RPn10a, and
Rpn10e, incubated with glutathione–agarose beads bound with GST-
ubiquilin, and then washed, resolved by SDS–PAGE, and analyzed by
Western blotting using anti-HA pAb. (B) Human HEK 293 cell lysates
were transiently transfected of one of two vectors, HA-tagged Rpn10a,
and Rpn3, incubated with glutathione-agarose beads bound with GST-
ubiquilin and GST-DUBL lacking the UBL domain (residues 113–
587). The binding ability was analyzed by Western blotting using anti-
HA pAb. Binding abilities of the mutants are shown in the right panel.
(C) HEK293 cells transiently transfected with plasmid for HA-tagged
Rpn10a in the presence or absence of FLAG-ubiquilin. Equal amounts
of cell lysates were immunoprecipitated with anti-FLAG mAb. The
immune complex bound to protein G-Sepharose beads was then wa-
shed with lysis buﬀer, resolved by SDS-PAGE, and analyzed by
Western blotting using anti-HA pAb (ﬁrst panel) and anti-FLAG mAb
(third panel). Total cell lysates were analyzed by Western blotting using
anti-HA pAb (second panel).
Fig. 4. Determination of the domain of Rpn10a that interacts with
ubiquilin. (A) The expression vectors encoding wild-type Rpn10a or
various deletion mutants fused with the GAL4 DNA-binding domain
were co-transformed with full-length ubiquilin fused with the GAL4
DNA-activating domain in AH109 cells. Each transformant was as-
sayed for b-galactosidase activity. (B) Summary of human Rpn10a
proteins. Binding abilities of the mutants are shown.
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was detected in immunoprecipitates with anti-FLAG from
cells co-transfected with Rpn10a-HA and FLAG-ubiquilin
(Fig. 3C).
3.4. Determination of the ubiquilin-binding domain in Rpn10a
It has been elucidated that Rpn10a interacts tightly with the
poly-Ub chains through a Ub-interacting motif (UIM) [18].
Rpn10a contains at least two independent UIM domains.
Hence, we attempted to determine which domain of Rpn10a is
required for interaction with ubiquilin using a two-hybrid
system. As shown in Fig. 4, the wild-type Rpn10a (1–377) and
1–262 mutants containing a UIM1 domain bound to ubiquilin,
whereas the 1–196 and 262–377 mutants lacking a UIM1 do-
main did not. These results indicate that the ubiquilin-binding
region is located within Rpn10a (197–262), which contains the
UIM1 domain.4. Discussion
4.1. Ubiquilin binds to multi-Ub chains
The aim of this study was to isolate and identify proteins
capable of interacting with PDI/ubiquilin, because we have
reported previously that up-regulation of ubiquilin by hypoxia
may be involved in the acquisition of tolerance against this
stress [5,6]. In the present study, we carried out yeast two-
hybrid screening to isolate proteins, and succeeded in charac-
terizing the Ub-fusion protein made up of UBA52 and Ub as a
protein that interacts with ubiquilin. This interaction was
mediated via the UBA domain of ubiquilin. The UBA domain
is a small domain composed of approximately 40 residues that
has thus far been identiﬁed in E2, E3, and other proteins linked
to ubiquitination. It has been proposed that the general
function of UBA domains in type 2 UBL proteins is to interact
with poly-Ub chains [19]. In mammalian cells, ubiquilin pref-erentially interacts with poly-Ub chains, but not with mono-
Ub, via its UBA domain (Figs. 1 and 2). In fact, it has been
reported that several Ub fusion proteins (UBI1, 2, 3) isolated
as the candidate proteins that interact with budding yeast
Dsk2p, a type 2 UBL protein in a yeast two-hybrid screening
[15]. However, they concluded that the binding between Dsk2p
and poly-Ub, but not mono-Ub, was evident. Taken together,
these results indicate that there were two reasons for the lack
of interaction between mono-Ub and ubiquilin in mammalian
cells: (1) ubiquilin speciﬁcally interacts with poly-Ub in a yeast
two-hybrid system and (2) the binding aﬃnity of poly-Ub is
more potent than that of mono-Ub. Thus, we speculated that
ubiquilin plays a critical role in the interaction with poly-Ub
chains, rather than in the interaction with mono-Ub. In ad-
dition, a signiﬁcant accumulation of poly-Ub chains was evi-
dent in ubiquilin-overexpressing cells (Fig. 2C). It has been
reported that observation of poly-Ub chains is dependent on
the preferential de-ubiquitination enzymatic activities that are
involved in the persistence of poly-Ub chains [20–22]. Thus,
the high content of ubiquilin in cells may function to stimulate
the formation of poly-Ub chains or inhibit the de-ubiquityla-
tion, and bind the poly-Ub proteins via its UBA domain.
4.2. Ubiquilin also associates with subunits of 19S proteasome
Poly-ubiquitylated proteins are ﬁrst recognized by interac-
tion with 19S regulatory complex and then degraded by the
20S core particle of proteasome. In particular, Rpn10, a sub-
unit of the 19S component, has been shown to bind tightly to
poly-Ub chains, but not to mono-Ub, and to be implicated in
the recognition of poly-Ub substrates in yeast [20–24]. In ad-
dition, the 19S base subunits Rpn1 and Rpn2 have previously
been identiﬁed as the receptor subunits for UBL domain
proteins in yeast [25,26]. On the other hand, hPLIC proteins
(ubiquilin-like proteins) have been reported to interact with
some 20S core complex subunits [17]. It has since been sug-
gested that not only HR23B but also hPLIC2 (ubiquilin 2)
interacts with S5a (Rpn 10a), a 19S component of 26S pro-
teasome [18,27]. Therefore, we here attempted to resolve the
question of whether or not ubiquilin associates with 19S pro-
teasome subunits in mammalian cells. Surprisingly, Rpn3,
Rpn10a, and Rpn10e possibly interacted with ubiquilin
through the UBL domain (Fig. 3). Although Rpn1 and Rpn2
can interact with UBL domains in yeast [25,26], we could not
actually observe the interaction between them. Unfortunately,
we do not have any clear evidence to demonstrate the diﬀer-
ences in interactions as seen in yeast and mammalian cells at
present. The diﬀerences may depend on a kind of UBL pro-
teins or species. Furthermore, we cannot exclude the possi-
bility that the interaction of ubiquilin with proteasome
subunits was not always direct, because a candidate protein
isolated by a yeast two-hybrid system sometimes shows the
bridged interaction with a target protein through another
protein. Recent reports suggest that Rpn10a interacts with a
poly-Ub chain-binding protein mediated by the multi-Ub
chain-binding sites, UIM1 (196–241) and UIM2 (263–307)
[28–30]. UIM2 has been shown to exhibit higher aﬃnity for
multi-Ub chains than UIM1 [30]. In this study, we tried to
elucidate the possible ubiquilin-binding region in Rpn10a. Our
results indicated that the region in Rpn10a responsible for the
interaction with ubiquilin is identical to its UIM1, but not its
UIM2 domain (Fig. 4A). Hence, the Rpn10a subunit located
in the 19S proteasome can interact with not only poly-Ub
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domain of ubiquilin. Taking these results together, we here
propose that ubiquilin may play a crucial function in mediat-
ing the protein degradation system via direct interaction with
both poly-Ub proteins and some subunits of the 19S protea-
some complex composed of base and lid sub-assemblies in
mammalian cells.
4.3. Possible involvement of ubiquilin in endoplasmic reticulum
(ER) stress-associated protein degradation
The adaptation in response to ER stress constitutes two dis-
tinct processes: an unfolded protein response (UPR) and an
ER-associated degradation (ERAD). Ubiquilin may be a pos-
sible target gene for UPR-induced transcription, since that
protein is induced by hypoxia (ER stress) [6]. Ubiquilin has been
identiﬁed as a protein that may interact with presenilin, which is
localized in the ERmembrane [31]. These authors demonstrated
that the ubiquilin staining pattern co-localized almost perfectly
with the presenilin staining pattern, strongly suggesting that
ubiquilin is an ER-membrane or ER-associated protein. Fur-
thermore, we have demonstrated that ubiquilin preferentially
interacts with PDI in vivo and in vitro [5,6]. From these ob-
servations, we speculated that the ability of ubiquilin in ER to
interact with both ubiquitylated proteins and the proteasome in
cytosol makes them likely adapter molecules for delivering
unfolded substrates to the proteasome in the ER.
UPR induces multiple ER and secretory pathway genes,
including ERAD-related genes. This system eliminates mis-
folded ER proteins via degradation through the Ub-protea-
some pathway in cytosol [32,33]. We considered that it would
be of interest to address the relationship between type 2 UBL
proteins, including ubiquilin located in the ER and in the
ERAD system, since recent exciting ﬁndings have suggested
the possibility that type 2 UBL proteins such as Herp and
Rad23 are implicated in the ERAD system [34,35]. Therefore,
these ﬁndings led us to conjecture that ubiquilin may play
some role in the ERAD system. We previously found that
PDI/ubiquilin up-regulation is involved in cell survival [5,6]. In
light of this ﬁnding, up-regulated ubiquilin may result in ac-
quisition of tolerance against stresses via control of the ERAD
system.
In summary, ubiquilin may be associated with poly-Ub and
subunits of the 19S proteasome in mammalian cells. Unfor-
tunately, the mechanism by which ubiquilin promotes the
degradation of the misfolded proteins remains unclear. Be-
cause the ERAD can be overwhelmed in several neurodegen-
erative diseases, including Alzheimer’s and Parkinson’s,
further analysis of the cellular and molecular mechanisms of
ubiquilin in the ER-stress-associated protein degradation
could lead to novel concepts in neurodegenerative diseases.
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